Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional Results available

A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors

ClinicalTrials.gov ID: NCT02563548

Public ClinicalTrials.gov record NCT02563548. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 4:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1B Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan-High Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 1b study evaluating a combination of PEGPH20 and pembrolizumab in hyaluronan-high (HA-high) participants with relapsed/refractory non-small cell lung cancer (NSCLC) and HA-high participants with relapsed/refractory gastric adenocarcinoma (GAC).

Study identification

NCT ID
NCT02563548
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Halozyme Therapeutics
Industry
Enrollment
56 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 21, 2015
Primary completion
Mar 25, 2019
Completion
Mar 25, 2019
Last update posted
Feb 6, 2020

2015 – 2019

United States locations

U.S. sites
28
U.S. states
19
U.S. cities
28
Facility City State ZIP Site status
University of Alabama at Birmingham Birmingham Alabama 35294
Mayo Clinic, Scottsdale, Arizona Scottsdale Arizona 85259-5499
California Cancer Associates for Research and Excellence - Encinitas Encinitas California 92009
University of California San Diego - Moores Cancer Center La Jolla California 92093
St. Joseph's Hospital Orange California 92868
University of California - Davis Sacramento California 95817
St. Joseph's Hospital Santa Rosa California 95403
Innovative Clinical Research Whittier California 90603
University of Colorado Denver University of Colorado Anschutz Medical Campus Aurora Colorado 80045
Georgetown University Medical Center Washington D.C. District of Columbia 20007
Holy Cross Hospitals Fort Lauderdale Florida 33308
University of Miami/Sylvester Cancer Center Miami Florida 33136
Cleveland Clinic Florida Weston Florida
Emory University Atlanta Georgia 30322
University of Chicago Chicago Illinois 60637
Ochsner Clinic Foundation New Orleans Louisiana 70121
Johns Hopkins Kimmel Cancer Center Baltimore Maryland 21231
Barbara Ann Karmanos Cancer Center Detroit Michigan 48201
Washington University School of Medicine St Louis Missouri 63130
New Jersey Hematology Oncology Associates Brick New Jersey 08724
University of Rochester Rochester New York 14642
Gabrail Cancer Center Canton Ohio 44718
Cleveland Clinic Cleveland Ohio 44195
Ohio State University Columbus Ohio 43210
Oregon Health and Science University Portland Oregon 97239
Mary Crowley Cancer Research Center Dallas Texas 75251
Virginia Cancer Specialists, PC Fairfax Virginia 22031
Swedish Health Services Seattle Washington 98104

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02563548, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 6, 2020 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02563548 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →